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1 
INTRODUCTION 
Urticaria is transient, well-demarcated, superficial erythematous or pale 
swellings of dermis, usually very itchy and associated with a surrounding red 
flare sometimes associated with angioedema. 
0.5 -1% of urticaria patients have chronic spontaneous urticaria. Chronic 
spontaneous urticaria affects the quality of life, causes depression and work 
absenteeism.  
2
nd
 generation antihistamines are the first line of management of chronic 
spontaneous urticaria. In patients who are not responding to antihistamine, their 
dose is increased upto four fold. 
Omalizumab is the third line of management in patients refractory to the 
antihistamine treatment of chronic spontaneous urticaria. It is a monoclonal 
antibody against the free IgE that prevents the binding of IgE FcRI receptors 
in the mast cells, thereby preventing the degranulation of mast cells. It is 
administered once in 4 weeks and adverse effects are few. The effectiveness is 
assessed by using Urticaria Activity Score(UAS7). 
In this study we administer Inj Omalizumab 300mg subcutaneously 
once in 4 weeks for 3 cycles and follow up the patient for 12 weeks and assess 
the effectiveness and safety of omalizumab in chronic spontaneous urticaria 
patients. 
2 
AIM: 
To assess the effectiveness and safety of Omalizumab in the treatment of 
Chronic Spontaneous Urticaria using Urticaria activity score 7 (UAS7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
REVIEW OF LITERATURE 
Urticaria is a mast cell driven disease. Rapid appearance of wheals 
and/or angioedema is a characteristic of urticaria, that is shared by all types of 
urticaria. 
 
Fig 1: Urticarial plaque over back. 
TERMINOLOGY: 
WHEAL: 
Transient, well-demarcated superficial pink or pale swellings of the 
dermis due to reversible exudation of plasma in the skin that fade, usually 
within hours without leaving a mark. 
4 
 
Fig 2: Wheals over knee joint 
Three typical features: 1. a central swelling of variable size, almost 
invariably surrounded by a reflex erythema, 2. associated itching or sometimes 
burning sensation, and 3.transient nature, with skin returning to its normal 
appearance usually within 1–24 hours.1 
ANGIOEDEMA: 
 
Fig 3: Angioedema of lip 
Sudden, pronounced deep swelling of lower dermis, subcutaneous or 
submucosal tissues. They are mostly painful rather than itchy. They are poorly 
defined and skin coloured. Resolution is slower than for wheals and can take 
5 
up to 72 hours.
1
Angioedema without wheals are either mast cell mediated 
(most common) or bradykinin mediated (less common). 
ANAPHYLAXIS: 
Acute, severe, life-threatening, generalized or systemic hypersensitivity 
reaction consists of diffuse erythema, pruritus, urticaria, angio-oedema, 
hypotension and difficulty in breathing. 
HISTORY 
The history of urticaria is fascinating and it partly reflected by many 
different names in the past. The earliest description of urticaria is found in 
Chinese tome. They used the term ‘Feng Yin Zheng’(wind type concealed 
rash). The ‘Urtica’ is the Latin word for nettles. In 4th century Hippocrates 
recognised the association of urticaria with nettles. ‘Urticadioica’- Sting of 
nettle. 
 The Romans focused on the burning (urere) at sites of wheals and 
Plinius introduced the name ‘Uredo’ meaning burning. In the 10th century, Hali 
Ben Abbas termed ‘Essera’ meaning mountain or elevation. In Indian 
Ayurvedic literature, it is ‘sheeta pitta’, meaning urticaria. In 18th century, 
Zedler termed the disease ‘Urticatio’ and in 1792 Frank coined the term 
‘Urticaria’. 
Borsch described Solar urticaria in 1719. Dermographism was first 
described by Heberden in 1767. Urticariapigmentosawas described by Edward 
6 
Nettleship (1869) and named by Sangster. Mast cells in lesions were described 
by Unna. Cholinergic urticaria was described by Duke in 1924. Shelley 
&Rawnsley in 1964coined Aquagenic urticaria and Shelley & Shelley in 1985 
termed Adrenergic urticaria. In 1882 Quincke described angioedema. In 1885 
Osler described cases of Hereditary angioedema. H1 anti histamines were 
discovered in 1937 by Bovet and Staub. 
EPIDEMIOLOGY 
INCIDENCE: 
One in five of the general population may develop urticaria in their life 
time. 
PREVALENCE: 
Global prevalence of chronic spontaneous urticaria is 0.5% -1%.
2 
It 
constitutes two third of the cases of chronic urticaria. 
AGE: 
Acute urticaria occurs more common in children. Chronic spontaneous 
urticaria affects all age groups but more common in second to fourth decades.
3 
SEX: 
Women to men ratio is 2:1 with chronic spontaneous urticaria.
3
No sex 
predilection is seen in acute spontaneous urticaria and inducible urticaria. 
7 
ASSOCIATED DISEASES: 
Acute urticariais commonly associated with upper respiratory tract viral 
infections, streptococcus pyogenes and Anisakis simplex. 
Chronic urticariais associated with helminthic infestations,
5 
active 
Helicobacterpylori infections
6
, coeliac disease in children
7
, dental and ENT 
infections, Candida infections of bowel, auto immune thyroid disease
8
, 
haematological malignancies and lymphoma.
9
 
PATHOPHYSIOLOGY: 
Urticarial skin lesions show recruitment of mast cells, basophils, 
neutrophils, eosinophils and T lymphocytes.
1,10-14
 
 
Fig: Inflammatory mediators of urticaria 
8 
Various pathways involved in the pathogenesis of urticaria are
15 
 
Fig: various pathways of urticaria 
 IgE or IgE receptor pathway,  
 Complement system,  
 Arachidonic acid pathway,  
 Direct mast cell degranulation  
Crosslinking of mast cell bound specific immunoglobulin E (IgE) by 
exogenous allergens may cause acute spontaneous urticaria. Binding of 
pathogen associated molecular patterns (PAMPs) on microbes to Toll-like 
receptors on mast cells may be the pathogenesis of acute urticaria. 
C5a complement is a co-factor for mast cell degranulation in vitro.
16 
Tryptase is released in conjunction with histamine. It can induce mast cell 
degranulation and cleave C3 to C3a and C3b. C3a can activate mast cells, and 
C3b can activate the alternative complement pathway. 
9 
 
Fig: Factors in the pathogenesis of urticaria 
Degranulation of mast cells and basophils by immunological or non-
immunological mechanism is the final step in the pathogenesis of urticaria. 
MEDIATORS FOR URTICARIA AND ANGIOEDEMA: 
PREFORMED MEDIATORS: 
 Histamine 
 Tumour necrosis factor recruit acute inflammatory cells, neutrophils 
and eosinophils into wheals. 
NEWLY FORMED MEDIATORS: 
 Prostaglandin D2 
 Platelet activating factors 
 Basophils cause prolongation of wheal response 
 Interleukin 8 
 Interleukin 10 
10 
ROLE OF HISTAMINE & IT’S RECEPTORS IN URTICARIA: 
HISTAMINE: 
It is synthesized by mast cells and basophils. It is released due to variety 
of stimuli. It mediates itching primarily by H
1
 receptor on the C nerve fibers 
which is a G protein coupled receptor attached to phospholipase CB3. It is the 
primary mediator in urticaria, mastocytosis, insect bite reactions and allergic 
drug reaction. It has four receptors in our body. 
H1 RECEPTORS: 
These receptors are located in smooth muscle cells, endothelium and 
central nervous system. They cause bronchoconstriction, vasodilatation, itch, 
flare, erythema, wheals, sleep and appetite suppression. 
H2 RECEPTORS: 
These receptors are located mainly in gastric parietal cells, vascular 
smooth muscle cells and keratinocytes. They are responsible for erythema, 
wheals and gastric acid secretion. 
H3 RECEPTORS: 
These receptors are seen in nervous system as inhibitory auto receptors 
and they decrease neuro transmitter release. These receptors are not found in 
human skin. 
11 
 
Fig: location of histamine receptors in skin 
 
H4 RECEPTORS: 
These receptors are found in eosinophils, basophils, mast cells and 
dendritic cells as well as bone marrow. They play an active role in chemotaxis. 
Activation of this receptor causes scratching behaviour in mice. 
 
 
12 
GENETIC PREDISPOSITION: 
Till date no predisposing factors for the development of spontaneous or 
inducible urticaria have been reported though several polymorphisms seems to 
be linked to aspirin-sensitive urticaria. There are very strong associations 
between patients with functional autoantibodies and HLA-DR4 in chronic 
spontaneous urticaria. 
CLASSIFICATION OF URTICARIA
1
: 
 
Fig: Classification of urticaria 
13 
CLASSIFICATION OF CHRONIC URTICARIA
1
:
 
 
Fig: Classification of chronic urticaria 
14 
ACUTE SPONTANEOUS URTICARIA: 
ETIOLOGY: 
 Idiopathic 
 Infections 
 Viral - upper respiratory tract infections, hepatitis B and C 
 Bacterial - Streptococcus pyogenes 
 Parasitic -Anisakis simplex 
 Foods -  cow’s milk, hen’s egg, nuts, seeds 
 Drugs– β-lactam antibiotics, aspirin 
 Stings -  bee, wasp venoms 
 Blood products -  transfusions 
 Vaccines 
 Contactants -  latex 
CHRONIC INDUCIBLE URTICARIA: 
DERMOGRAPHISM: 
On stroking the skin there will be TRIPLE RESPONSE of local 
erythema due to capillary vasodilation, followed by edema and a surrounding 
flare due to axon reflex-induced dilatation of arterioles. 
15 
 
Fig: Dermographism 
Pathogenesis: 
Mast cells sensitised with immunoglobulins(IgE) react with neoantigen 
induced by mechanical stimulation of skin resulting in release of mediators. 
Types of dermographism: 
1. Red dermographism – appears following rubbing instead of stroking. 
2. Cholinergic dermographism - it resembles multiple small urticarial 
papules of cholinergic urticaria. 
3. Delayed dermographism- it appears after 3-6 hours and persist upto 48 
hours. It is usually tender.  
4. White dermographism- it occurs due to capillary vasoconstriction 
following light stroking. It is seen in normal people but more 
pronounced in atopic dermatitis. 
5. Black dermographism– the discolourisation is due to pressure from 
metallic objects. 
16 
VIBRATORY URTICARIA: 
They are described as an autosomal dominant familial form but an 
acquired form is seen occasionally. Any vibratory stimulus like jogging, 
vigorous towelling induces localised urticaria within minutes, lasting for few 
hours. 
PRESSURE URTICARIA: 
Immediate: 
Wheal occurs within minutes of applying perpendicular pressure to the 
skin and persist for 30 min to few hrs. eg., leaning against furniture,handling a 
steering wheel, crossing legs. 
Delayed (DPU): 
It appears after a delay of 30 min to 9 hrs and lasts upto 12 to 72 hrs. 
They are itchy and often tender over soles and scalp. Urticaria appear at the site 
of tight clothing (waist line), hands after manual works, prolonged sitting on 
buttocks and lower back and feet on walking. Pressure exacerbates chronic 
spontaneous urticaria to some extent. It is associated with systemic symptoms 
like malaise, arthralgia as well as with delayed dermographism and cold 
urticaria. 
17 
 
Fig: Pressure urticaria 
HEAT URTICARIA: 
Heat urticaria is the rarest form of physical urticaria. It is more common 
in women. Localized warming of skin at temperatures around 38 to 44° C 
induces wheals. It starts in 2-5 min and last for 1-3 hours.  
COLD URTICARIA: 
Primary cold urticaria: 
Commonest form occurring in young adults. Itching and wheals occur 
within minutes of exposure to cold. Cold rain and cold wind are effective 
stimuli. Systemic symptoms like flushing, palpitations, headache, wheezing, 
loss of consciousness and drowning may occur. 
 
Fig: Demonstration of cold urticaria 
18 
Secondary cold urticaria: 
This type of cold urticaria is secondary to cryoproteins. It is associated 
with other conditions like Raynaud phenomenon, purpura or skin necrosis. 
Systemic cold urticaria: 
Generalised wheals occurs in response to cooling of the core body 
temperature. 
COLINERGIC URTICARIA: 
It accounts for 5% of chronic urticaria and is common in adolescents 
and more common during winter. Wheals appear after sweating and is due to 
stimulation of the cholinergic postganglionic sympathetic nerve supply to the 
sweat glands. 
SOLAR URTICARIA: 
On exposure to visible, long or short wave UV radiations, wheals appear 
with in minutes at exposure sites but disappear within 2 hours. 
a. Primary– it is idiopathic. It is more common in women and systemic 
symptoms are seen in severe cases. 
b. Secondary- it occurs secondary to porphyria cutaneatarda, erythropoietic 
porphyria, systemic lupus erythematosus and drugs like tetracycline, 
chlorpromazine. 
 
19 
c. Delayed type 
d. Fixed solar urticaria- it is inducible at particular wave length between 300-
700nm.It is idiopathic but sometimes occurs secondary to porphyria. 
AQUAGENIC URTICARIA: 
Occurrence of wheals with wide flare on contact with water of any 
temperature. It usually disappears in 30-60 minutes after contact with water. 
Other urticaria induced by water are cold urticaria, cholinergic urticaria and 
dermographism. Aquagenic pruritis without wheals occurs over the legs and 
lower trunk. 
CONTACT URTICARIA: 
Allergic type: 
In an individual who has already developed specific IgE to an allergen 
contact will elicit type 1 hypersensitivity response which causes mast cell 
degranulation with release of histamine causing wheal and flare. The 
commonest cause are latex and food like nuts, fruits, fish. 
 
Fig: Pathogenesis of allergic type of contact urticaria 
20 
 
Non allergic type: 
It is caused by direct injection of vasoactive chemical by plants or 
animals or exposure to cosmetics (cinnamic aldehyde, balsam of Peru) or food 
additives (benzoicacid, sorbic acid). This is due to the formation of 
prostaglandin D2 and not histamine release. 
CHRONIC SPONTANEOUS URTICARIA: 
Based on EAACI/GA2LEN/EDF/WAO guidelines,
 
Chronic spontaneous urticaria is defined as spontaneous (without 
external physical triggers), sudden appearance of wheals, and/or angioedema 
lasting more than 6 weeks duration.
3 
NATURAL COURSE OF CHRONIC SPONTANEOUS URTICARIA: 
Duration of CSU is estimated to be 1-5 years of diagnosed CSU 
population:
3,17 
 
 
21 
DEFINITION OF REFRACTORY CHRONIC SPONTANEOUS 
URTICARIA: 
Chronic spontaneous urticaria that does not respond to standard of care, 
is labelled as refractory urticaria.
11 
The standard of care for chronic 
spontaneous urticaria is the non-sedating H1antihistamines (cetirizine, 
loratadine, fexofenadine, etc.). The duration of non-response to standard of care 
has to be at least 2 weeks to classify the patient as refractory chronic 
spontaneous urticaria. 
 
Fig: Refractory chronic spontaneous urticaria 
 
IMPACT OF URTICARIA ON QUALITY OF LIFE(QOL): 
 
QOL is affected in chronic spontaneous urticaria due to its impact on the 
activities of daily living, self-perception, social aspects, treatmentrelated 
effects, and mainly the psychological status of the patient.
21
 The psychological 
aspects of QOL contribute to work productivity, absenteeism and thereby have 
financial implications. Occurrence of angioedema further impairs the quality of 
life.
22 
22 
 
Fig: Factors impact the quality of life in CSU 
 
PROGNOSTIC FACTORS FOR CSU DURATION: 
 More severe disease
3,18
 
 Concurrent angioedema
3,18
 
 Concurrent inducible urticaria
3,19
 
 A positive autologous serum skin test
3,20
 
 
PATHOGENESIS OF CHRONIC SPONTANEOUS URTICARIA(CSU): 
Although the exact trigger of CSU is unknown, it is hypothesized that 
there is a repeated and extensive activation of the dermal mast cells.
23
 This 
leads to degranulation of cutaneous mast cells and the release of histamine 
(preformed) and other mediators (newly formed) such as prostaglandins, 
endogenous peptides, endorphins, and enkephalins.
24
 This causes wheal 
23 
formation, vasodilatation, and erythema. Histamine released from the mast 
cells, prostaglandins, endogenous peptides, endorphins, enkephalins, and also 
chemoattractant from other cells such as neutrophils also mediate in the process 
of wheal formation.  
The threshold for mastcell activation and degranulation is lowered in 
patients with CSU. Autoimmune mechanisms are involved in CSU in about 
45% cases and the remaining 55% remain idiopathic.
25 
Either IgG 
autoantibodies to the alpha subunit of the Fc receptor of the IgE molecule or 
anti-IgE autoantibodies can activate basophils to release histamine. These 
antibodies are reported to be specific to CSU.
26,27
 
Antithyroid antibodies are reported to be positive in 27.3% (33% males 
and 25% females) of patients with chronic spontaneous urticaria.
28
 
 
Fig: Mast cell activation in CSU 
Histamine release 
24 
Angioedema rarely occurs in isolation in chronic spontaneous 
urticaria
29,30
 and it results from release of inflammatory mediators (histamine, 
cytokines) after mast cell degranulation.
23,24 
HISTOPATHOLOGY: 
The histopathologic features show non-specific changes in urticaria. 
Acute urticaria shows dilated venules, endothelial swelling. In chronic urticaria 
dermis shows features of perivascular & interstitial infiltrate (lymphocytes, 
eosinophils, neutrophils). On electron microscopy, dermal mast cells show 
signs of degranulation. 
 
25 
DIFFERENTIAL DIAGNOSIS: 
The possible differential diagnosis are: 
HIVES ANGIOEDEMA 
 Acquired auto inflammatory disorders 
eg. 
o Schnitzler´s syndrome 
o systemic-onset juvenile 
idiopathic arthritis 
o adult-onset Still’s disease 
 Hereditary autoinflammatory 
disorders eg. 
o Cryopyrin associated periodic 
syndromes such as 
 familial cold auto-
inflammatory 
syndromes  
 Muckle-Wells 
syndrome   
 neonatal onset 
multisystem 
inflammatory disease  
 hyper-IgD syndrome   
 TNF receptor alpha-
associated periodic 
syndrome  
 Urticarial vasculitis 
 
 Hereditary angioedema  
 Acquired angioedema due 
to C1-inhibitor deficiency  
 Angiotensin converting 
enzyme nhibitor- induced 
angioedema 
 
Table 1: Differential diagnosis of urticaria 
URTICARIAL VASCULITIS: 
This is the most common differential diagnosis for chronic urticaria. It is 
characterized clinically by presence of urticarial wheals for >24 hrs. It is Type 
III hypersensitivity reaction.  It is more common in middle aged women. It 
26 
manifests as burning and pain rather than itching. Trunk and proximal 
extremities are commonly involved. It resolves with residual staining. 
Hypocomplementic urticarial vasculitis syndrome (HUVS):  
It is associated with connective tissue diseases (SLE, Sjogren’s), viral 
infections (Hep B&C, EBV), neoplasms (IgM gammopathies), drugs 
(NSAIDS, KI, fluoxetine). It has systemic features like migratory arthralgia 
(50%), lymphadenopathy, hepatosplenomegaly, respiratory, GIT, renal and 
ocular manifestations. Complement level is the indicator of severity & marker 
for prognosis. Low C1q, C4 (occasionally C3, C5, CH50), presence of anti C1q 
auto antibody and lowC1q level seen in 100% pts of HUVS 
Normocomplementic urticarial vasculitis syndrome(NUVS):  
It is common (70-80%) and limited to the skin. High erythrocyte 
sedimentation rate and microscopic proteinuria are seen. 
Urticaria Urticarial vasculitis 
Lasts < 24 hrs. 
More itching. 
Recur at different sites. 
Systemic features not uncommon. 
Etiology- variable. 
No residual pigmentation. 
HPE- non-specific. 
Treatment-antihistamines 
> 24 hrs. 
 burning, painful and tender. 
 may recur at same sites. 
 common. 
CTD, infections, malignancy. 
Dusky hue staining. 
Features of vasculitis. 
Dapsone, Hydroxychloroquin,  colchicin 
Table 2: Difference between urticaria and urticarial vasculitis 
27 
DIAGNOSTIC ALGORITHM OF CHRONIC SPONTANEOUS 
URTICARIA:
1 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Fig: EAACI/GA
2
LEN/EDF/WAO urticaria guidelines: Diagnostic algorithm. 
 
His
tor
y 
Di
ag
no
sti
c 
tes
ts 
Tr
eat
me
nt 
Recurrent unexplained fever? 
Joint/bone pain? Malaise? 
ACE inhibitor treatment? 
+ + - - 
+ - + - - + - + 
+ - - + 
- + 
Signs of 
vasculitis in 
biopsy? 
Are symptoms 
inducible? 
Provocation test 
Acquired/ 
hereditary 
AID 
Urticarial 
vasculitis 
Chronic 
spontaneous 
urticaria 
Chronic 
inducible 
urticaria 
HAE I–III 
AAE 
ACE-
inhibitor 
induced AE 
Interleukin-1 Histamine and other Mast Cell Mediators Bradykinin 
and/
or 
Auto-
inflammatory 
disease? 
Average hive 
duration >24 
hours? 
HAE or AAE? Remission 
after stop? 
Hive
s 
Angioedema 
28 
DIAGNOSIS OF CHRONIC SPONTANEOUS URTICARIA: 
Thorough history and physical examination is the most important 
diagnostic procedure. 
 H/O urticaria - timing, frequency and duration of attacks;  
 H/O wheals -shape, size, distribution and associated symptoms of 
lesions; 
 Family history 
 Medical history, including allergies; correlation to any triggers, e.g., 
food, exercise, drug use;  
 H/O aggravating factors like work, hobbies, smoking habits, and stress;  
 Previous therapy and response to treatment;  
 H/O to exclude physical urticaria, urticarial vasculitis, and inducible 
urticaria. 
INVESTIGATIONS: 
 Blood haemoglobin, 
 Differential blood count,  
 Erythrocyte sedimentation rate, 
 Absolute eosinophil count, 
 Serum IgE levels, 
 Liver function test, 
 Renal function test, 
29 
 Anti nuclear antibody, 
 C‑ reactive protein, 
 ELISA for HIV, 
 RPR for syphilis, 
 HBsAg and anti-HCV, 
 Chest X-ray and Mantoux test, 
 ECG and Echocardiograph, 
 Stool for ova and cyst, 
 Thyroid profile, 
 Anti-thyroid antibodies, 
 Autologous serum skin test, 
 ENT, Dental, cardiology and chest physician opinions are obtained. 
AUTOLOGOUS SERUM SKIN TEST(ASST): 
1986, Grattan et al were the first to use ASST to differentiate 
autoimmune urticaria from chronic spontaneous urticaria. The patient was 
injected intradermal 0.1 ml of autologous serum and normal saline as control. 
The positive results were arbitrarily defined as formation of a wheal by serum 
within 2 h of injection that is at least 5 mm larger than that resulting from 
saline control and had a difference of 10 mm in the diameter of surrounding 
erythema. ASST positivity indicates auto immune urticaria. ASST results tend 
to get modified with treatment. The patients should not take antihistamines for 
30 
at least 2-3 days, long-acting antihistamine for 7 days prior to the test to avoid 
false negative results. 
URTICARIA ACTIVITY SCORE -7(UAS7): 
SCORE  WHEALS SCORE 
ITCH SEVERITY 
SCORE (ISS) 
0 NONE None None 
1 MILD <20 wheals/24 h Present but not annoying 
or troublesome 
2 MODERATE 20–50 wheals/24 h Troublesome but does 
not interfere with 
normal daily activity or 
sleep 
3 INTENSE >50 wheals/24 h or 
large confluent 
areas of wheals 
Severe pruritus, which is 
sufficiently  troublesome 
to interfere with normal 
daily activity or sleep 
UAS7 is a weekly composite score of the itch severity score (ISS) and 
number of hives score (0-42) and used to measure disease activity.
1,31
 
 
 Weekly itch severity score is the sum of daily ISS over 7 days. 
 Weekly number of hives score is the sum of the daily number of wheals 
score over 7 days. 
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CATEGORIZATION OF SEVERITY 
 
Fig: Categorization of severity of CSU 
AIM OF TREATMENT: 
The main aim is to decrease the effect of mast cell and/or basophil 
mediators on the target organs leading to the symptoms of urticaria.
1,3 
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TREATMENT ALGORITHM FOR CHRONIC SPONTANEOUS 
URTICARIA IN INDIA: 
 
33 
1
ST
 LINE OF MANAGEMENT OF CHRONIC SPONTANEOUS URTICARIA: 
SECOND GENERATION H1 ANTIHISTAMINES: 
These are the first line treatment for all patients with chronic 
spontaneous urticaria.
1
 They are rapidly absorbed, reaches peak serum 
concentration in 1-3 hrs. Second generation non sedative H1 antihistamines are 
now the treatment of choice. 
Advantages: 
 Non sedative at recommended doses. 
 Minimal anticholinergic side effects. 
2
nd
 generation anti histamines are:  
 Cetirizine  
 Levocetrizine 
 Loratadine 
 Desloratadine 
 Fexofenadine 
 Mizolastine 
 Rupatadine. 
CETRIZINE: 
Cetrizine is given as 10mg/day. It is poorly metabolized in liver and 
elimination is through urine. It is rapid absorbed. Its enantiomer levocetrizine is 
also used in the treatment of chronic spontaneous urticaria. Cetrizine may cause 
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sedation at therapeutic as well as supra therapeutic dose, whereas levocetirizine 
does not have the potential of causing sedation at supratherapeutic dose. 
LORATADINE: 
Loratadine is prescribed in the dose of 10mg daily and it is metabolized 
in the liver by CYP3A4. Desloratadine is given in the dose of 5mg daily. 
Desloratadine is non sedative. 
FEXOFENADINE: 
Fexofenadine with adult dose of 180mg/day is the active metabolite of 
terfenadine but without cardiotoxicity at clinically relevant doses and has 
widest therapeutic window. It is eliminated via liver. Two long-term studies in 
healthy volunteers have demonstrated that fexofenadine, at doses upto 240 mg 
once daily for upto 12 months, is safe and well tolerated.
32
 No dose-related 
increase in QT interval (QTc) were found with fexofenadine doses up to 800 
mg once daily or 690 mg twice daily for 28 days.
33
 Fexofenadine does not lead 
to sedation at therapeutic as well as supratherapeutic doses. 
Limitations: 
They do not influence the disease course. 
Adverse effects: 
 Sedation 
 Mizolastine blocks HERG1 channels so cautious use is adviced with 
drugs that prolong Q-T interval. It may also cause electrolytic 
disturbance. 
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2
nd
 LINE OF MANAGEMENT OF CHRONIC SPONTANEOUS 
URTICARIA: 
Second generation anti histamines can be increased upto 4 times of their 
licenced dose
34
.  This has been verified in studies using even up to 
fourfoldhigher than recommended doses of desloratadine,
35
fexofenadine,
36
 
levocetirizine
37
and rupatadine.
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SHORT COURSE OF CORTICOSTEROIDS: 
Prednisolone has predominant glucocorticoid activity and is commonly 
used for longterm disease suppression. Oral corticosteroids i.e., prednisolone 
0.5mg/kg/day is used for short period of 3-7 days to control severe attacks of 
urticaria and angioedema.
39
 Prolonged use is avoided due to the risk of side 
effects. 
3
rd
 LINE OF MANAGEMENT OF CHRONIC SPONTANEOUS 
URTICARIA: 
Montelukast: 
It is a leukotriene receptor antagonist. It does not work in all types of 
urticaria. It works well for aspirin-sensitive urticaria.
40
 A study found 
montelukast monotherapy ineffective in CSU when compared with 
cetirizine.
41
Dailydosage is 10 mg taken at bedtime. There are no important 
drug interactions. 
36 
Cyclosporine: 
Cyclosporine is a powerful inhibitor of both cell mediated and humoral 
responses. It inhibits the release of histamine from basophils and tumor 
necrosis factor α production by mast cells42. There are many reports of efficacy 
of cyclosporine in urticaria.
43,44
 Dosage of cyclosporine 3-5 mg/kg as a starting 
dose and tapered over three to four months. Onestudyshowed that prolonged 
treatment with cyclosporine is beneficial for maintaining remission in severe 
cases of chronic urticaria. Lowdose (2–3 mg/kg) therapy has also shown its 
beneficial effect in controlling urticaria.
45
Generally, the duration of 
cyclosporine therapy is 3 months. It spares the need for corticosteroids and is 
accompanied with mild side effects.
46
 
Contraindications: 
 Impaired kidney function  
 Uncontrolled blood pressure 
 Active serious infections  
 Malignancy 
Adverse effects: 
 Renal dysfunction 
 Hypertension 
 Hyperkalemia 
 Hyperuricemia 
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 Hypomagnesemia 
 Hyperlipidemia 
OMALIZUMAB: 
Omalizumab is a humanized IgG1 monoclonal antibody47 
manufactured by recombinant DNA technology in a Chinese hamster ovary 
mammalian cell line. It selectively binds to human IgE. 
 Humanization of murine anti-IgE was done to reduce the potential for 
human anti-mouse antibody response. 
 
 
 
 
 
 
 
 
Fig: structure of omalizumab 
Murine CDRs 
(5% of molecule) 
IgG1 kappa  
human 
framework 
(95% of molecule) 
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Fig: binding of Omalizumab to C3 domain of IgE 
 
 Omalizumab binds to the C3 domain of IgE, forming trimers or 
hexamers
48,49
 and  preventing it from binding to FcRI on the surface of 
mast cells and basophils 
 Omalizumab cannot bind to receptor bound IgE.  
 
INDICATIONS: 
FDA approved indications: 
 Chronic spontaneous urticaria refractory to standard 1st and 2nd line of 
management in patients of age more than 12 years. 
 Allergic asthma 
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DOSE SCHEDULE: 
Omalizumab is administered by subcutaneous route which either comes 
in prefilled syringe or with lyophilised formulation for reconstitution. 
The approved dose is 300 mg (2 x 150mg once in 4 weeks). 
 
SHELF LIFE: 
4 years 
PRECAUTIONS FOR STORAGE: 
 It is stored in a refrigerator at 2-8°C. The drug should not be freezed.  
 After reconstitution, omalizumab has to be used immediately. It should 
not be used after 8 hours at 2-8°C or 2 hours at 25°C. 
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MECHANISM OF ACTION: 
The exact mechanism of action of omalizumab in chronic spontaneous 
urticaria is unknown.  
 
Fig: Mechanism of action of Omalizumab in CSU 
One hypothesis for the mechanism of action of omalizumab in chronic 
spontaneous urticaria is that it lowers free IgE levels in the blood and 
subsequently in the skin. This leads to downregulation of surface IgE receptors, 
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thereby decreasing downstream signalling via the FcεRI pathway, resulting in 
suppressed cell activation and inflammatory responses. As a consequence, the 
frequency and severity of symptoms of chronic spontaneous urticaria are 
lessened. 
 Another hypothesis is that lowering circulating free IgE levels leads to a 
rapid and nonspecific desensitization of cutaneous mast cells. Downregulation 
of FcεRI may help to sustain the response.50 
PHARMACOKINETIC PROPERTIES: 
ABSORPTION: 
After subcutaneous administration, the absolute bioavailability is 62%. 
It is absorbed slowly, reaches peak serum concentrations after an average of  
6-8 days. 
DISTRIBUTION: 
In vitro omalizumab forms complexes of limited size with IgE. Based on 
population pharmacokinetics, the volume of distribution following 
subcutaneous administration is 78±32 ml/kg based on its lyophilised or liquid 
formulation. 
ELIMINATION: 
Clearance of omalizumab involves IgE clearance processes as well as 
clearance via specific binding and complex formation with its target ligand, 
IgE. Degradation occurs in the reticuloendothelial system and endothelial cells. 
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On population based pharmacokinetics, its serum eliminationhalf-life at 
steady state is about 24 days and apparent clearance at steady state for a patient 
of 80 kg weight was 3ml/kg/day. 
CHARACTERISTICS IN PATIENT POPULATIONS: 
No dose adjustments are necessary in patients with chronic spontaneous 
urticaria for 
 Age (12-75 years) 
 Race/Ethnicity 
 Gender 
 Body weight 
 Body mass index, 
 Baseline IgE 
 Anti-FcεRI auto antibodies 
 Renal impairment 
 Hepatic impairment 
 Concomitant use with H1 or H2 antihistamines and leukotriene 
antagonist.  
CONTRAINDICATIONS: 
 Hypersensitivity to active substance or any of its excipients 
 Age less than 12 years 
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 It should not be used in pregnancy as it crosses placenta but its harm to 
foetus is unknown. (pregnancy category B). 
 It should not be given during breast feeding as in non-human primates 
have shown excretion of omalizumab into milk. 
 Parasitic(helminthic) infestations. 
ADVERSE EFFECTS:
51,52 
 Sinusitis and upper respiratory tract infections 
 Head ache 
 Pyrexia 
 Arthralgia 
 Injection site reaction 
 Anaphylaxis 
 Arterial thromboembolic events 
 Vasculitis and systemic eosinophilia in patients with Churgstrauss 
syndrome 
 Idiopathic thrombocytopenia 
 Increase in rate of helminthic infection 
EFFECT OF OMALIZUMAB ON IgE: 
In clinical studies of chronic spontaneous urticaria patients, omalizumab 
treatment led to a dose-dependent reduction of free IgE and an increase of total 
IgE levels in serum. Maximum suppression of free IgE was observed 3 days 
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after the first subcutaneous dose. After repeated dosing once every 4 weeks, 
predose serum free IgE levels remained stable between 12 and 24 weeks of 
treatment. Total IgE levels in serum increased after the first dose due to the 
formation of omalizumab: IgE complexes which have a slower elimination rate 
compared with free IgE.  After discontinuation of omalizumab, free IgE levels 
increased and total IgE levels decreased towards pre-treatment levels over a 
16weekstreatment free followup period.
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STUDIES ON EFFICACY AND SAFETY OF OMALIZUMAB IN 
CHRONIC SPONTANEOUS URTICARIA (CSU): 
There are three important landmark studies on the use of Omalizumab in 
chronic spontaneous urticaria.  
First is a 24 weeks treatment with omalizumab 300 mg (n = 81), 
omalizumab 150 mg (n = 80), omalizumab 75 mg (n = 78), and placebo  
(n = 80) followedby a 16 weeks of followup in CSU management (ASTERIA I 
study).
53 
The second study was ASTERIA II study which was a 12week 
treatment with omalizumab 300 mg (n = 79), omalizumab 150 mg (n = 83), 
omalizumab 75 mg (n = 82), and placebo (n = 79) followed by 16 weeks 
followup,
54
 and 
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The third study was GLACIAL study which was a global, multicentre, 
randomized, double blind, placebo controlled study of safety and efficacy of 24 
weeks treatment with omalizumab 300 mg (n = 252) versus placebo (n = 84).
51
 
In the above three studies, a total of 733 patients having CSU received 
omalizumab, and it was found to be effective and safe in the dose of 300 mg 4 
weekly injections (subcutaneous). There was a 62–71% reduction in itch with 
omalizumab from baseline at 12 weeks, 34–44% of patients were itch free and 
hive free with omalizumab at 12 weeks, and 73–78% had improvement 
indermatology life quality index scores at 12 weeks, respectively. Common 
side effects observed were headache, joint pain, injection site reactions, and 
upper respiratory infections. 
In 24 months followup study, of the 16 patients with severe CSU using 
fixed dose omalizumab (150 mg 2–4 weekly), 10 patients (62%) had remission 
after the first injection of omalizumab, and two patients discontinued therapy.
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Of the 14 patients, four patients remained in remission for over 9 months after 
the last injection, and seven patients continued to be in remission with 
continuing maintenance therapy of antihistamines.  
In another study presented in the annual conference of the American 
Academy of Allergy, Asthma, and Immunology (20–24 February2015) in 
Houston, Texas, 30 patients (15 male/15 female) with treatment resistant CSU 
being treated with omalizumab were followed for up to 4 years, with 15 
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patients completing 4 years treatment.
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 Complete remission was seen in 9/30 
(30%) patientsafter the second dose, and there were significant improvements 
in UAS between pretreatment and first dose, with mean of 3.9, (95%confidence 
interval 3.45–4.3) which was maintained throughoutthe 4th year of therapy. 
Omalizumab was a safe and effectivealternative to corticosteroid for refractory 
urticaria patients. It isequally effective and safe for long term use up to 4 years. 
 Although there are no reports of comparative studies of omalizumab in 
Indian patients, there are two reports published earlier. First is a single case 
study of 45year old female who presented with severe CSU since 10 years of 
age not responding to antihistamines and steroids.
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 The patient was treated 
with cyclosporine for sarcoidosis and incidentally her urticaria responded to 
cyclosporine. Considering the autoimmune aetiology for CSU, omalizumab 
was administered to this patient and the patient’s response for CSU was 
dramatic.  
The second report is a case study of omalizumab in five patients with 
CSU.
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 These five patients had severe urticaria that required multiple 
antihistamines, steroids, or dapsone to control symptoms and in spite of 
therapy, they had severe symptoms. In the absence of recommended dose for 
omalizumab in CSU, the patients were treated with omalizumab according to 
the dose schedule of asthma. There was a significant improvement in all the 
patients, with reduction in UAS7 and need of antihistamines. At the end of 4 
months, two patients were free from symptoms and the other three required 
47 
only antihistamines to control their symptoms. Side effects were recorded in 
two patients in the form of headache and fatigue. 
THE USE OF OMALIZUMAB IN CHRONIC SPONTANEOUS 
URTICARIA IN INDIA
59 
The following recommendations were issued on the use of omalizumab for 
treatment of chronic spontaneous urticaria in India: 
 Omalizumab is approved in adults and adolescents ≥12 years of age 
with chronic spontaneous urticaria refractory to standard of care by the 
Health authority of India.  
 Assessment of the severity of chronic spontaneous urticaria to be done 
using UAS7 score. 
 Serum IgE measurement is not needed before the start of omalizumab 
therapy for chronic spontaneous urticaria. 
 It is recommended as the third line therapy for management of chronic 
spontaneous urticaria by EAACI/GA2LEN/EDF/WAO 2013 guidelines.  
 Omalizumab should only be administered in a setting where the 
appropriate medications and equipment are available to respond to an 
episode of anaphylaxis. 
 Recommended dose and best response are seen with 300 mg 
subcutaneous injection once in 4 weeks. Because the solution is slightly 
viscous, the injection may take 5–10 seconds to administer. 
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 Body weight measurement is not required for calculating the dose of 
omalizumab. 
 Ice compress may be applied at site of injection to minimize local 
reactions. 
 All patients administered omalizumab to be observed for 2 hrs after 
dosage for any allergic reactions. 
 Dose of omalizumab in patients with hepatic/renal compromised status 
may remain same (i.e., 300 mg once every 4 weeks). 
 Omalizumab should only be used during pregnancy if clearly needed.  
 Caution should be exercised when administering omalizumab to a 
nursing woman. 
SPECIAL PRECAUTIONS ADMINISTRATION AND DISPOSAL: 
For subcutaneous administration Inj omalizumab 150mg, 
 1.2 ml of the diluent is drawn into a syringe with a large bore 18 gauge 
needle. 
 The vial is placed upright on a flat surface, the needle is inserted and the 
diluent is transferred to the vials containing the lyophilised powder 
under aseptic techniques. 
 The vial is kept in an upright position, vigorously swirled (not to be 
shaked) for approximately 1 minute to evenly wet the powder. The vial 
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has to been swirled 5-10 seconds approximately every 5 minutes so that 
the powder gets dissolved. 
 The reconstituted injection appears as clear to slightly opalescent, 
colourless to pale brownishyellow. 
 The vial is inverted for atleast 15 seconds in order to allow the solution 
to drain towards the stopper.  
 A new 2ml syringe is used to draw the reconstituted solution from the 
vial. The air and large bubbles are expelled. 
 After reconstitution, omalizumab has to be used immediately. It should 
not be used after 8 hours at 2-8°C or 2 hours at 25°C. 
 The injection is administered in the deltoid region of the arm or the 
thigh. 
 The patient has to be monitored for vitals and any adverse effects. 
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MATERIALS AND METHODS 
STUDY DESIGN: 
Non probability - convenience sampling 
Prospective Study 
STUDY POPULATION: 
 Sample size -30 
STUDY DURATION: 
 1 year 
PLACE OF STUDY:   
Department of Dermatology 
Govt. Stanley Medical College 
INCLUSION CRITERIA: 
 Both sex  
 Age >12 years 
 Patients refractory to updosing of antihistamines. 
 Patients willing for informed consent 
 Patients willing for follow up 
EXCLUSION CRITERIA: 
 Hypersensitivity to drug 
 Pregnancy 
 Lactation 
 Parasitic infestations 
 Tuberculosis/HIV/Hepatitis 
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SCREENING VISIT: 
 Thorough history of the patients was taken. Patients were assessed and 
selected based on the inclusion and exclusion criteria. Written informed 
consent was obtained. Clinical assessment of the condition was carried out. 
STUDY PLAN:  
 
The patients who fulfilled the inclusion criteria and willing to take part 
in the study were screened. After obtaining informed written consent, 
therewere admitted in our Dermatology ward and administered Inj 
Omalizumab 300mg subcutaneously. Patients were monitored for vitals and 
any adverse reactions. Patients were advised to maintain urticaria activity 
score7(UAS7) and reviewed weekly as outpatient. The patient was advised to 
come for next 2 doses of Inj Omalizumab 300mg every 4 weeks and followed 
up for next 12 weeks. The safety and effectiveness was studied by using 
urticarial activity score7(UAS7). 
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INVESTIGATIONS: 
The following investigations were done at the start of the study 
(screening visit)   
 Blood haemoglobin 
 Platelet count 
 Total count 
 Differential blood count 
 Erythrocyte sedimentation rate 
 Absolute eosinophil count 
 Serum IgE levels. 
 Liver function test 
 Renal function test 
 Anti nuclear antibody 
 C-reactive protein 
 ELISA for HIV 
 RPR for syphilis 
 HBsAg 
 Anti HCV 
 Chest X-ray and Mantoux test 
 ECG and Echocardiograph 
 Stool for ova and cyst 
 Thyroid profile 
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 Autologous serum skin test 
MONITORING PARAMETER: 
 Patients were monitored every week clinically with URTICARIA 
ACTIVITY SCORE 7 
 Adverse events were analysed at each follow up visit. 
 Patient compliance was confirmed at every follow up visit. 
CLINICAL EFFECTIVENESS ASSESSMENT BY PATIENTS USING 
URTICARIA ACTIVITY SCORE 7. 
 At each of the visits, clinical effectiveness was assessed as follows: 
Week No: 
Day  Itch severity score Wheals score 
Day 1   
Day 2   
Day 3   
Day 4   
Day 5   
Day 6   
Day 7   
 
The urticaria activity score7 was analysed during treatment period of 12 weeks 
and during the follow up period of another 12 weeks. 
54 
OBSERVATION AND RESULTS 
Statistical methods are extensively used in modern medical research. 
Statistical methods like, descriptive statistics, correlation analysis, t-test, chi-
square test, ANOVA have become some of the most common applications of 
statistical methods in medical research.  
AGE-WISE DISTRIBUTION: 
Age wise distribution of study population 
Age Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 
< 20 Years 2 6.7 6.7 6.7 
20 - 40 Years 17 56.7 56.7 63.3 
> 41 years 11 36.7 36.7 100.0 
Total 30 100.0 100.0  
 
 
Fig: Age-wise distribution of study population 
 
In this study the 56.7% are between 20 – 40 years of age, followed by 
36.7% are more than 41 years of age. 
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SEXWISE DISTRIBUTION OF PATIENTS 
Sex No of patients Percent Valid Percent 
Cumulative 
Percent 
 
Male 7 23.3 23.3 23.3 
Female 23 76.7 76.7 100.0 
Total 30 100.0 100.0  
 
 
 
 
 
 
 
 
Fig: Sexwise distribution of study population 
Females constituted 77% and males 23% of study population. 
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PRETREATMENT CLASSIFICATION OF CSU: 
 
Pre Treatment Category 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 
Mild CSU 3 10.0 10.0 10.0 
Moderate CSU 15 50.0 50.0 60.0 
Severe CSU 12 40.0 40.0 100.0 
Total 30 100.0 100.0  
 
 
 
 
Fig: Pretreatment classification of CSU 
 
90% of the pretreatment study population are under the category of 
moderate to severe CSU. 
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OCCUPATION WISE DISTRIBUTION OF STUDY POPULATION: 
Table: Occupation wise distribution 
Occupation Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 
BUSINESS 2 6.7 6.7 6.7 
COOLIE 4 13.3 13.3 20.0 
HOUSE KEEPER 1 3.3 3.3 23.3 
HOUSE WIFE 13 43.3 43.3 66.7 
OFFICE ASST 2 6.7 6.7 73.3 
PLUMBER 1 3.3 3.3 76.7 
STUDENT 4 13.3 13.3 90.0 
TEACHER 3 10.0 10.0 100.0 
Total 30 100.0 100.0  
 
 
Fig: Occupation wise distribution of study population 
 
Out of the several occupational groups, Housewives wife consisted 43% 
of the study population. It was inferred that the urticarial was troublesome in 
doing day to day household activities and so a large no of patients reported the 
Dermatology OPD. 
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PREVALENCE OF URTICARIA IN STUDY POPULATION: 
Table: Prevalence of urticaria in years 
No of years of 
urticaria 
No of people 
 
Percent 
Valid 
Percent 
Cumulative 
Percent 
 
1 3 10.0 10.0 10.0 
2 6 20.0 20.0 30.0 
3 3 10.0 10.0 40.0 
4 1 3.3 3.3 43.3 
4 3 10.0 10.0 53.3 
5 1 3.3 3.3 56.7 
6 3 10.0 10.0 66.7 
7 2 6.7 6.7 73.3 
8 2 6.7 6.7 80.0 
9 1 3.3 3.3 83.3 
12 1 3.3 3.3 86.7 
13 1 3.3 3.3 90.0 
14 1 3.3 3.3 93.3 
19 1 3.3 3.3 96.7 
20 1 3.3 3.3 100.0 
Total 30 100.0 100.0  
 
This table show the highest prevalence of urticariain years in this study 
population is 20 years. 
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OCCURRENCE OF CSU – DAYS/WEEK: 
Table: Occurrence of urticaria  per week 
Days/week 
urticarial 
present 
No of 
patients 
Percent Valid Percent 
Cumulative 
Percent 
 
2 1 3.3 3.3 3.3 
3 3 10.0 10.0 13.3 
4 5 16.7 16.7 30.0 
5 9 30.0 30.0 60.0 
6 6 20.0 20.0 80.0 
7 6 20.0 20.0 100.0 
Total 30 100.0 100.0  
 
 
 
Fig: Occurrence of urticaria - days/week. 
 
Most of the study population (21 pts) had incidence of urticarial lesions 
more than 5 days per week. 
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TOTAL NUMBER OF URTICARIAL LESIONS PER DAY: 
Table: Total number of urticarial lesions per day 
Number of 
urticarial 
lesions 
No of 
patients 
Percent Valid Percent 
Cumulative 
Percent 
 
10 1 3.3 3.3 3.3 
20 3 10.0 10.0 13.3 
25 5 16.7 16.7 30.0 
30 3 10.0 10.0 40.0 
35 2 6.7 6.7 46.7 
40 4 13.3 13.3 60.0 
50 7 23.3 23.3 83.3 
60 2 6.7 6.7 90.0 
70 2 6.7 6.7 96.7 
80 1 3.3 3.3 100.0 
Total 30 100.0 100.0  
 
 
Fig: Number of urticarial lesions per day in the study population 
 
40% of the study population had more than 50 wheals per day. This 
prevented them to do their day to day activities effectively. 
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ANGIOEDEMA IN THE STUDY POPULATION: 
Table: Angioedema 
Angioedema 
No of 
patients 
Percent 
Valid 
Percent 
Cumulative 
Percent 
 
NO 27 90.0 90.0 90.0 
YES 3 10.0 10.0 100.0 
Total 30 100.0 100.0  
 
Only 10% of the study population had angioedema. 
 
ASST POSITIVITY IN THE STUDY POPULATION: 
Table: ASST positivity 
ASST Result Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 
Negative 28 93.3 93.3 93.3 
Positive 2 6.7 6.7 100.0 
Total 30 100.0 100.0  
 
Only 6.7% of the study population were ASST positive i.e., they had 
auto immune urticaria. 
ABSOLUTE EOSINOPHIL COUNT IN THE STUDY POPULATION: 
Table: Absolute eosinophil count 
AEC 
No of 
patients 
Percent 
Valid 
Percent 
Cumulative 
Percent 
 
Normal level 25 83.3 83.3 83.3 
Increased 5 16.7 16.7 100.0 
Total 30 100.0 100.0  
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Fig: Absolute eosinophil levels in study population  
83% of the study population had normal eosinophil count. 
SERUM IgE LEVELS IN THE STUDY POPULATION: 
 
 
 
Table: Serum IgE levels 
Serum IgE levels Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 
Normal 11 36.7 36.7 36.7 
Increased 19 63.3 63.3 100.0 
Total 30 100.0 100.0  
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Fig: Serum IgE levels of the study population 
63% of the study population had increased serum IgE levels. 
II. Categorical data analysis: 
Qualitative or categorical data are frequently collected in medical 
investigation. The qualitative variables include Sex, blood groups, Attacked or 
not attacked as well as the grouped quantitative variables such as in control, 
mild, severe. 
 When the interest lies in the association between two qualitative 
variables, then the frequencies can be presented in a two-way table or cross 
table. 
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Cross tabulation and Chi square analysis: 
 
RELATION SHIP OF ANGIOEDEMA, AEC AND SERUM IgE LEVELS 
WITH SEX: 
 
Sex Vs Angioedema 
 Angioedema 
Total 
No Yes 
Sex 
Male 
Count 6 1 7 
%  85.7% 14.3% 100.0% 
Female 
Count 21 2 23 
%  91.3% 8.7% 100.0% 
Total 
Count 27 3 30 
% within SexCode 90.0% 10.0% 100.0% 
 
 
Fig: sex vs angioedema in the study population 
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Sex Vs Absolute eosinophil count 
 AEC 
Total 
Normal increased 
Sex 
Male 
Count 7 0 7 
%  100.0% 0.0% 100.0% 
Female 
Count 18 5 23 
%  78.3% 21.7% 100.0% 
Total 
Count 25 5 30 
% within SexCode 83.3% 16.7% 100.0% 
 
Sex Vs Serum IgE levels 
 Serum IgE levels 
Total 
Normal Increased 
Sex 
Code 
Male 
Count 2 5 7 
% within SexCode 28.6% 71.4% 100.0% 
Female 
Count 9 14 23 
% within SexCode 39.1% 60.9% 100.0% 
Total 
Count 11 19 30 
% within SexCode 36.7% 63.3% 100.0% 
 
b). CHI-SQUARE TEST FOR ASSOCIATION 
When the interest is to determine whether the proportion of 
improvement or success rate in one group (say treatment group) differs 
significantly from a control group. The most commonly used statistical method 
is the Chi-Square test. This test is used to test whether there is any association 
between the two groups or  the success rate in treated group differs from a 
control group. The Chi square test compares the difference between the 
observed counts and the expected counts in a contingency table. If the 
differences are large, then the two variables under the investigation ae likely to 
be associated with each other.  
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Using Chi square the relationship between sex and angioedema, AEC 
and serum IgE were analysed. Chi square revealed that the angioedema, 
Absolute eosinophil count and serum IgE are not related to sex. 
 
III.Correlation Analysis: 
One of the common objectives of the study is to investigate the 
relationship between two characteristics of a population. The correlation 
coefficient can be used to test whether there is any linear relation between the 
variables in the population. The t statistic can be used to test the null hypothesis 
that the population correlation coefficient is 0. 
 
CORRELATION BETWEEN OCCURRENCE OF URTICARIA PER 
WEEK, NUMBER OF YEARS AND NUMBER OF LESIONS PER DAY: 
 Occurrence of 
urticariaper 
week 
Number 
of years 
Number of 
lesions per 
day 
Occurrence 
of urticaria 
per week 
Pearson Correlation 1 .120 .015 
Sig. (2-tailed)  .526 .936 
N 30 30 30 
Number of 
years 
Pearson Correlation .120 1 .012 
Sig. (2-tailed) .526  .950 
N 30 30 30 
Number of 
lesions per 
day 
Pearson Correlation .015 .012 1 
Sig. (2-tailed) .936 .950  
N 30 30 30 
 
Number of Urticarial lesions per day and its occurrence per week are 
uncorrelated, r (30) = .015, p= .936  
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Number of years andoccurrence of Urticariaper week are uncorrelated, r 
(30) = .120, p = .526, 
Number of years and Number of urticarial lesions per day uncorrelated, 
r (30) = .012,  p = .950, 
 
The three variables Number of years, Occurrence of urticaria per week 
and Number of urticarial lesions per day are not linearly correlated. 
 
IV. TESTING OF HYPOTHESES 
 The statistical frame work employs probability distributions to evaluate 
how close is the proposed hypothesis to the sample and hence the population 
from which is drawn. All tests in this study are tested at Level of 
significance α = 5% (= .05) 
 
a). Independent samples T-Test 
     Very often, in medical research, a researcher encounters the problem of 
comparing two groups on a continuous outcome. This is to test whether on an 
average, one group is significantly higher or lower than the other. Here the two 
groups are male and female and the continuous outcomes are 1. Number of 
years, 2. Occurrence of utricaria per week and Number of lesions. 
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INFLUENCE OF SEX ON NUMBER OF YEARS, OCCURRENCE OF 
URTICARIA PER WEEK AND NUMBER OF LESIONS: 
 
Sex 
Code 
N Mean 
Std. 
Deviation 
Std. Error 
Mean 
Number of years 
Male 7 6.14 4.337 1.639 
Female 23 5.93 5.382 1.122 
Occurrence of urticaria per 
week 
Male 7 5.14 1.069 .404 
Female 23 5.14 1.459 .304 
Number of lesions  
Male 7 37.86 9.940 3.757 
Female 23 40.87 18.869 3.934 
 
1).      Male (M = 6.14, S.D = 4.33) and female ( M = 5.93, S.D = 5.38 )  did 
not differ significantly on Number of years , t ( 28 ) = .093, p = .926. 
2).      Male (M = 5.14, S.D = 1.07) and female ( M = 5.14, S.D = 1.46 )  did 
not differ significantly on Occurrence of urticaria per week, t ( 28 ) = 
..01, p = .999. 
3).      Male (M = 37.86, S.D = 9.94) and female ( M = 40.87, S.D = 18.87 )  
did not differ significantly on Number of urticarial lesions , t ( 28 ) = 
..402, p = .691 
Inference: In the study based on Independent Sample T test, the sex had 
no influence on (1) Number of years, (2) Occurrence of urticarial per week and 
(3) Number of urticarial lesions. 
b) Oneway ANOVA 
 
three categories of age(less than 20 years, between 21 and 40 years and 
more than 41 years) were considered and testedwhether the mean Numbers of 
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years, mean AEC and mean Serum IgE level differs among the three categories 
of age. 
The test is done under the null hypothesis H0 that the mean Numbers of 
years, mean AEC and mean Serum IgE level do not differ significantly due to 
age is tested against the alternative hypothesis that at least one age group is 
different from other age groups. 
INFLUENCE OF AGE OVER NUMBER OF YEARS, AEC & SERUM IgE: 
 
Sum of Squares df 
Mean 
Square 
F Sig. 
Number 
of years 
Between Groups 364.608 2 182.304 .607 .552 
Within Groups 8109.559 27 300.354   
Total 8474.167 29    
AEC 
Between Groups 62121.722 2 31060.861 1.504 .240 
Within Groups 557737.078 27 20656.929   
Total 619858.800 29    
Serum 
IgE 
Levels 
Between Groups 187609.504 2 93804.752 1.808 .183 
Within Groups 1400709.424 27 51878.127   
Total 1588318.928 29    
 
From one-way ANOVA the inference of this study is, the number of 
years, AEC and serum IgE levels did not differ due to the age. 
c)  Paired  t    tests: 
         The context of paired samples arises in studies comparing the difference 
in outcomes before and after an intervention and twin studies where the 
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measurement on one entity is related to the measurement on the other and thus, 
the observations are dependent. When the outcomes are continuous in nature, 
the means are compared using a paired samples test such as paired t test.   
In this study the null Hypothesis H0, that the treatment is ineffective, is  
tested against the alternative hypothesis H1 ,  namely the treatment is effective, 
over different periods of study 
 
(i) Paired t test 1 Effectiveness of intervention during treatment period): 
Paired Samples Statistics – treatment period 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 
PreTreatWK1 26.59 29 8.305 1.542 
TreatWK12 5.4138 29 3.56087 .66124 
 
Paired Samples Correlations –treatment period 
 N Correlation Sig. 
Pair 1 PreTreatWK1 & TreatWK12 29 .560 .002 
 
Paired Samples Test –treatment period 
 Paired Differences t df Sig.  
(2-tailed) 
Mean Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
 
Lower Upper 
Pair 
1 
PreTreatWK1 - 
TreatWK12 
21.172
41 
6.96455 1.29328 18.52324 23.82159 16.371 28 .000 
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Fig: comparison of UAS7 during treatment period 
 
A paired sample t test indicated that scores were significantly higher for 
PreTreatWK1 ( M = 26.59, S.D  = 8.31 ) than for TreatWK12  
(  ( M = 26.59, S.D  = 8.31 ) ,  t (28)=  16.37 ,  p< .001 
Inj omalizumab had rapid and sustained improvement in the reduction of 
UAS7 score during the treatment period. 
Paired t- Test  2 ( Effectiveness during follow-up period) 
 
Paired Samples Statistics –follow up period 
 
Mean N Std. Deviation 
Std. Error 
Mean 
Pair 1 
TreatWK12 4.9615 26 3.28001 .64326 
Follow up 
WK24 
5.1538 26 4.16358 .81654 
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Paired Samples Correlations –follow up period 
 N Correlation Sig. 
Pair 1 
TreatWK12 & followup 
WK24 
26 .692 .000 
 
Paired Samples Test – follow up period 
 Paired Differences 
t df 
Sig.  
(2-
tailed) Mean 
Std. 
Deviatio
n 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 
1 
TreatWK12 -  
Follow 
upWK24 
-.19231 3.03340 .59490 -1.41753 1.03291 -.323 25 .749 
 
 
 
Fig: comparison of UAS7 during follow up period 
A paired sample t test indicated that scores were not significantly differ 
for  Treat WK12 -  ( M = 26.15, S.D  = 26.15) and for   follow upWK24 (  ( M 
= 5.1538, S.D  = 4.16358) ,  t (25)=  .323 ,   p= .749 
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In the analysis it was found that there is no significant reduction in the 
UAS7 score from the treatment week12 to follow up week 24. 
(iii) Paired T-Test (Entire study period) 
 
Paired Samples Statistics – Entire study period 
 
Mean N 
Std. 
Deviation 
Std. Error 
Mean 
Pair 
1 
PreTreatWK1 26.15 26 26.15 1.551 
FollowupWK24 5.1538 26 4.16358 .81654 
 
Paired Samples Correlations –Entire study period 
 N Correlation Sig. 
Pair 1 
PreTreatWK1 
&followupWK24 
26 .563 .003 
 
Paired Samples Test – Entire study period 
 Paired Differences 
t df 
Sig.  
(2-
tailed) Mean 
Std. 
Deviati
on 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 
PreTreatWK1 
– follow up 
WK24 
21.00
000 
6.54217 1.28303 
18.3575
6 
23.6424
4 
16.3
68 
25 .000 
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Fig: comparison of UAS7 entire study period 
Pt 2,6 and 9 lost follow up. 
A paired sample t test indicated that scores were significantly higher 
forPreTreatWK1 ( M = 26.15, S.D  = 26.15) than for   Follow up WK24 (  ( M 
= 5.1538, S.D  = 4.16358) ,  t (28)=  16.37 ,  p< .001 
From paired t test, InjOmalizumabwas effective in drastically reducing 
the UAS7 from pretreatment period to treatment week12 and their effectiveness 
was good, but from Treatment week 12 to follow up week 24, the effectiveness 
of Omalizumabwasnot significant. After the treatment period, there was no 
significant improvement. Overall the effectiveness of omalizumab in this study 
population varied between patients. 
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SUMMARIZING STUDY DATA 
The more commonly used summary measures are 1. Arithmetic mean or 
mean and 2. Standard deviation. While mean will do the role of a 
representative (location of a central value), the standard deviation will tell the 
closeness of the to the central value.  
Descriptive measures on USA7 scores during the study period 
 Pre 
treat 
Treat 
WK4 
Treat 
WK8 
Treat 
WK12 
Follow up 
Wk16 
Follow up 
Wk20 
Follow up 
Wk24 
Mean 26.40 7.97 6.10 5.41 4.79 5.48 5.15 
Standard 
Deviation 
8.22 4.74 4.08 3.56 3.18 4.04 4.16 
Number 30 30 29 29 29 27 26 
 
 
Fig: Mean UAS7 for the entire study period 
There is a rapid and sustained improvement in the mean UAS7 during the 
treatment period and there is a slight surge in the mean UAS7 in the follow up 
period.  
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Gantt chart 
A Gantt chart is a type of bar chart that illustrates a project schedule. 
Gantt charts illustrate the start and finish dates of the terminal elements and 
summary elements of a project. Terminal elements and summary elements 
comprise the work breakdown structure of the project. Modern Gantt charts 
also show the dependency (i.e., precedence network) relationships between 
activities. 
Transition to lower level ( cure)  during the study period.  Gantt chart 
Categorization Pre T4 T8 T12 PoT4 PoT8 PoT12 
Severe  (28 – 42) 12       
Moderate ( 16- 27) 15 1      
Mild ( 7 – 15 ) 3 18 16 13 11 11 10 
Well controlled  
( 1 – 6) 
    1     9 13    15    13     13 
Itch and Hive free 0  
(Zero) 
  4 3 3 5 5 
 
 
The table illustrates the fact that during the follow-up period,  a good 
number of people are still in mild state, indicates the drug has no sustenance. 
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DISCUSSION: 
CSU was most common in the age group of 20-40years which is similar 
to the Maurer et al in which the commonest age group is 20-40 years. 
The female: male ratio was 3:1 which is slightly higher than Maurer et 
al where the ratio was 2:1. Among females most of them were house wives. 
There is no association of age or sex with angioedema, serum IgE level 
and Absolute eosinophil count. 
The prevalence of ASST positivity in our study was 6.7% which was 
less when compared to the prevalence of ASST positivity in patients of chronic 
urticaria in various studies varing from 35 to 58%.
61-64
 
There was no relationship between number of years, number of 
urticarial lesions and occurrence of urticaria per week. 
  From paired t test the following inference was made. Inj Omalizumab is 
effective in controlling the disease. From the pre- treatment to treatment 
week12 there was rapid and sustained improvement in the UAS7 score. It was 
foundthat during the follow up period there was a slight surge in the UAS7 
score and the effectivenesss of Omalizumab was not significant. After the 
treatment period, there was no significant improvement in the UAS7 score. But 
the response varies from one another in the study population. This was similar 
to the study done by Maurer et al where there was a sustained improvement in 
the UAS7 during treatment period.
54 
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The mean UAS 7 score for the entire study population drastically 
decreased from pre treatment period to follow up period which was similar to 
the ASTERIA I and ASTERIA II study. 
UAS 7 has two components i.e., itch severity score and wheals score. 
After the administration of Inj Omalizumab it was found that there was 
dramatic decrease in the wheals score component of UAS7 while there was a 
minimal decrease in the itch severity score component. The remission period of 
urticaria symptoms in this study varies from 3 to 4 months in few patients when 
compared with ASTERIA II study where there was an average remission 
period of 6 to 9 months. 
The adverse effect recorded in this study period was Pseudoscleroderma 
after the administration of omalizumab I dose. The patient was deferred 
Omalizumab and the patient is under investigation to find whether the adverse 
effect was due to omalizumab or co incidental. 
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CONCLUSION 
Omalizumab is the third line of management in the treatment of chronic 
spontaneous urticaria refractory to four-fold increase in 2
nd
 generation 
antihistamines. In this study, a study population of 30 patients were selected by 
convenient sampling and after their informed consent, they were administered 
3 doses of Inj Omalizumab 300mg subcutaneously once in every four weeks 
and the effectiveness of Omalizumab is assessed by Urticaria Activity Score 7. 
The patients are followed up for 3 months by the UAS7 and the data are 
analysed.   
The conclusions of this study are  
 The common age group is between 20-40 years and the female:male 
ratio is 3:1.  
 There is no relation between angioedema, serum IgE levels and 
Absolute eosinophil count with either sex or age. 
 The occurrence of urticaria per week, the number of years of urticaria 
and number of urticarial lesions per day are uncorrelated among 
themselves.  
 There is a rapid and sustained improvement in the UAS7 during the 
treatment period of 12 weeks compared to the baseline UAS7. But there 
is no significant improvement during the follow up period. 
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 Most of the patients in the follow up period the patients were maintained 
with 2
nd
 generation anti histamines.  
 There is a dramatic fall in the wheals score of UAS7 whereas the itch 
severity score still persisted during the follow up period.  
 One patient had pseudosclerodema following first dose of omalizumab. 
 Inj Omalizumab 300mg subcutaneously can be given once in 4 weeks 
unless otherwise contraindicated. 
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ANNEXURE  - ABBREVATIONS 
EAACI = European Academy of Allergy and Clinical Immunology; 
GA2LEN = Global Allergy and Asthma European Network; 
EDF = European Dermatology Forum; 
WAO = World Allergy Organization 
CSU = Chronic Spontaneous Urticaria 
QOL = Quality of life 
UAS7 = Urticaria Activity Score 7 
ISS = Itch Severity score 
SLE = systemic lupus erythematosus 
EBV = Ebstein Barr Virus 
NSAIDS = Non-steroidal anti-inflammatory drugs 
KI = Pottasium Iodide 
IgA = Immunoglobulin A 
IgE = Immunoglobulin E 
ELISA = Enzyme Linked Immuno Sorbent Assay 
HIV = Human Immunodeficiency Virus 
RPR = Rapid Plasma Reagin 
ECG = Electrocardiogram 
OPD = Outpatient department 
Fcɛ R1 = Fc epsilon R1 receptor 
     PROFORMA 
Name      Age:    Sex: 
Occupation:        Marital Status: 
Address: 
 
Phone No: 
1.H/O  itchy raised skin lesions: 
 Incidence per week: 
 Number of lesions: 
 Duration of lesions: 
 Resolution by: 
2. itching: 
3. Fever 
4. Pain over lesion: 
5.any contact with plants: 
6. aggravation after food: 
7. exacerbation after sun exposure: 
8. exacerbation after cold exposure: 
9. exacerbation followed by pressure: 
10. exacerbation after water exposure: 
11. exacerbation followed by any drugs: 
12. any H/O swelling of lips  
13. H/O difficulty in breathing 
14. H/O swallowing of food 
15. H/O any chest pain 
16. H/O abdominal pain 
17. H/O any infections 
18. H/O loss of weight 
19.H/O loss of appetite 
20.H/O altered bowel and bladder habits. 
21 previous treatment history 
22. menstrual history 
23. Personal history 
24. Vitals: pulse rate:  BP:  RR: 
25.Other system: 
26. Dermatology examination 
 
 
ASST: 
Urticaria Severity Score 7: 
Investigations: 
 Complete blood count: 
 
 Renal function test: 
 
 Liver function test: 
 
 Absolute eosinophil count: 
 Serum IgE levels: 
 ICTC: 
 HBsAg: 
Anti HCV: 
Chest X ray: 
ECG: 
Autologous serum skin test (ASST): 
Thyroid profile: 
 
 
   
 
 
RLYp A±dûL 
 
AWÑ vPôu− UÚjÕYUû]«p úRôp ©¬®p Ah¬dúL¬Vô Gu\ 
úSôn Es[YoL°Pm JUô−ÑUôl Gu\ UÚk§u Bt\p Utßm TdL 
®û[ÜLû[ A±Rp Tt±V BnÜ SPjRlTÓ¡\Õ. 
CkR BnÜ UÚ.®.B]kRu AYoL°u RûXûU«p, UÚ.NôWRô 
AYoL°u ER®úVôÓ UÚ.A²Rô ¡±v¥Vôp SPjRlTÓ¡\Õ. 
CkR Bn®p EeL°u TeúLt× Øt±Ûm Ru²fûNVô]Õ. CkR 
Bn®p ¿eLs TeúLtTRtÏ Øu×. C§p EeLs úSôndLô] UÚkÕ 
Tt±Ùm, Nôj§VUôÏm TVuLs, TdL ®û[ÜLs Tt±Ùm CkR RLYp 
T¥Yj§p EeLÞdÏ á\lTÓm. 
SôsThP ¿¥j§ÚdÏm Ah¬dúL¬Vô úSôndÏ KUô−ÑUôn Gu\ 
UÚkÕ úRôp F£VôL UôRm JÚ Øû\ êuß UôReLÞdÏ EeLÞdÏ 
A°dLlTÓm. 
CkR úSôn A¬l×, R¥l× HtTÓjÕm IgE Gu\ CmØú]ôÏúXô©u 
GuTRtÏ G§WRôL ùNVpTÓ¡\Õ. CR]ôp A¬l× Utßm R¥l× Ïû\¡\Õ. 
EeL°u UÚjÕY YWXôß Utßm RtúTôûRV BúWôd¡V ¨ûX 
Tt± úLs®Ls úLhLlTÓm. EeLÞdÏ Cf£¡fûN A°dÏm Øu £X 
T¬úNôRû]Ls ùNnVlTÓm. 
úUÛm CkR Bn®p TeúLtTRôp áÓRXôL GkR TVàm, GkR 
®û[Üm CpXôUp úTôLXôm. EeLÞdÏ RûXY−, LônfNp, F£ 
úTôÓm CPj§p ùRôkRWÜ Utßm A]©Xd£v B¡V TdL ®û[ÜLs YW 
Yônl× Es[Õ. B]ôp AkR Yônl× ªL ªL A¬Õ. 
A¬l× YWXôß Utßm LÓûUjRuûU ®YWeLs ûLúVôÓ êXm 
úNL¬dLlÓm. UÚjÕY¬Pm AÓjR YÚûL YûW AûR ¨WlT EeL°Pm 
G§oTôodLlTÓ¡\Õ. 
C§p ØÝU]ÕPu TeúLtL ®Úm©]ôp Jl×Rp T¥Yj§p 
ûLùVÝj§PUôß úLhÓ ùLôs¡ú\ôm. 
 
ASSESSMENT OF EFFECTIVENESS AND SAFETY OF OMALIZUMAB IN THE 
TREATMENT OF CHRONIC SPONTANEOUS URTICARIA 
 
Investigator:   Dr. S Anitha Christy  MD.D.V.L 1st yr 
Guide:    Dr.V.Anandan (Professor & H.O.D) 
    Dr. Afthab Jameela Wahab (Associate Professor) 
    Dr K.P Saradha (Asst Professor) 
Patient Information Module 
You are being invited to be a subject in this study. 
Before you participate in this study, I am giving the following details about this 
trial, which include the aims, methodology, intervention, possible side effects, if 
any and outcomes 
All patients diagnosed with  chronic urticaria will be included in this study. A 
detailed clinical history will be taken following a standardized proforma. A 
clinical examination and relevant basic investigation will be done. They will be 
administered omalizumab and followed up in our outpatient department for a 
period of 1 year at regular intervals 
The result arising from this study will be analysed and used for academic 
purposes. You will be given clear instructions at every step and you are free to 
ask/clarify any doubts. Your identity remains confidential. You are free to 
withdraw from the trial at any point of time, without any prior notice &/or 
without any medical or legal implications. 
I request you to volunteer for this study 
Thanking You 
 
 Investigator’s Sign                       Patient’s Sign 
(Dr. S Anitha Christy)             Name: 
   
 
KEY TO MASTER CHART 
 N.O.Y – Number of years 
 UR.LE – Urticarial lesions 
 D/WK – Days /week 
 N.L –Number of lesions 
 ANG – Angioedema 
 AEC – Absolute eosinophil count 
 S.I.L –Serum IgE level 
 ASST –Autologous serum skin test 
 LFU – Lost follow up 
wk 1 wk 2 wk 4 wk 8 wk12 wk16 wk20 wk24
1 40 F TEACHER 4 3 50 YES 180 298.6 + 19.1.16 20.2.16 23.3.16 33 36 13 11 9 7 10 8 NIL
2 31 m BUSINESS 13 5 30 NO 360 405.2 - 19.1.16 20.2.16 21.3.16 40 38 20 15 14 12 12 LFU NIL
3 41 F HOUSE WIFE 6 7 20 NO 420 174 - 20.1.16 24.2.16 24.3.16 16 24 12 9 8 7 7 7 NIL
4 25 F HOUSE WIFE 2 3 25 NO 722 254.5 - 27.1.16 25.2.16 29.3.16 27 31 12 11 10 8 5 5 NIL
5 38 F HOUSE WIFE 12 4 70 NO 220 114 + 5.2.16 5.3.16 3.4.16 36 33 1 0 0 1 6 4 NIL
6 18 F STUDENT 2 5 30 NO 443 312.6 - 7.2.16 13.3.16 17.4.16 16 21 8 6 6 3 LFU LFU NIL
7 35 F COOLIE 4 6 35 NO 194 537 - 8.2.16 8.3.16 7.4.16 31 31 11 7 7 8 8 7 NIL
8 45 F HOUSE WIFE 3 5 40 YES 296 766.3 - 24.2.16 26.3.16 24.4.16 27 28 13 9 4 3 3 3 NIL
9 30 M COOLIE 5 6 50 YES 240 253.8 - 26.2.16 1.4.16 30.4.16 35 33 9 9 8 6 LFU LFU NIL
10 21 F STUDENT 1 5 40 NO 304 715.3 - 18.7.16 18.8.16 18.9.16 26 26 4 4 3 3 2 1 NIL
11 41 F HOUSE WIFE 8 4 20 NO 400 119.8 - 28.7.16 29.8.16 29.9.16 28 34 3 1 2 6 9 12 NIL
12 32 F HOUSE WIFE 3 2.3 60 NO 230 321.4 - 29.7.16 29.8.16 29.9.16 14 16 9 7 5 4 4 4 NIL
13 29 F TEACHER 2 7 25 NO 228 112.3 - 2.8.16 1.9.16 30.9.16 15 14 3 0 1 1 0 0 NIL
14 47 f HOUSE WIFE 7 7 35 NO 40 124.2 - 19.8.16 19.9.16 19.10.16 38 34 12 6 9 9 14 14 NIL
15 45 F COOLIE 20 7 70 NO 146 239 - 17.8.16 19.9.16 19.10.16 27 32 11 10 9 8 14 15 NIL
16 58 F HOUSE WIFE 2 6 50 NO 88 25.8 - 19.8.16 19.9.16 17.10.16 14 16 1 0 0 0 1 1 NIL
17 32 M PLUMBER 6 4 30 NO 189 814.3 - 31.8.16 3.10.16 4.11.16 38 40 10 7 7 7 7 7 NIL
18 38 F HOUSE KEEPER 3.5 7 60 NO 445 692 - 19.9.16 1.11.16 3.12.16 35 32 14 11 9 9 9 10 NIL
19 33 M BUSINESS 8 5 25 NO 122 156 - 17.10.16 25.11.16 29.12.16 22 26 1 1 1 1 3 2 NIL
20 27 F TEACHER 4 4 50 NO 118 342 - 24.10.16 23.11.16 22.12.16 27 29 9 9 7 7 7 7 NIL
21 29 M OFFICE ASST 1 5 40 NO 400 543.3 - 28.10.16 30.11.16 30.12.16 17 14 6 3 3 2 1 1 NIL
22 18 F STUDENT 2 6 25 NO 324 119.1 - 5.11.16 5.12.16 4.1.17 38 38 10 7 7 5 5 5 NIL
23 52 F HOUSE WIFE 14 3 10 NO 89 231.6 - 14.11.16 13.12.16 12.1.17 18 16 7 7 5 5 4 4 NIL
24 48 F HOUSE WIFE 7 5 50 NO 252 196.7 - 22.11.16 21.12.16 21.1.17 23 24 6 3 3 3 2 2 NIL
25 44 M COOLIE 9 7 40 NO 218 567 - 6.12.16 5.1.17 5.2.17 27 25 10 9 6 4 4 4 NIL
26 31 F HOUSE WIFE 3 5 20 NO 387 124 - 18.12.16 16.1.17 14.2.17 20 19 4 1 1 0 0 0 NIL
27 56 F HOUSE WIFE 19 6 25 NO 119 328 - 4.1.17 3.2.17 4.2.17 28 26 8 6 5 3 4 4 NIL
28 23 M STUDENT 1 4 50 NO 232 673.4 - 11.1.17 10.2.17 12.2.17 19 22 1 0 0 0 0 0 NIL
29 49 F OFFICE ASST 6 5 80 NO 365 107.3 - 22.1.17 23.2.17 25.3.17 36 34 10 8 8 7 7 7 NIL
30 33 F HOUSE WIFE 2 6 50 NO 443 660 - 4.2.17 DEFERRED 21 15 1DEFFERED DUE TO PSEUDOSCLERODERMA
I dose II dose III dose
OMALIZUMAB
SIDE 
EFFECTS
PRE 
TREATMEN
T
TREATMENT 
PERIOD
FOLLOW UP 
PERIODS.NO AGE SEX
OCCUPATIO
N
N.O.Y S.I.L ASST
UR.LE
D/WK N.L
ANG AEC
